Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease

被引:118
|
作者
Di Minno, Matteo Nicola Dario [1 ]
Russolillo, Anna [1 ]
Lupoli, Roberta [1 ]
Ambrosino, Pasquale [1 ]
Di Minno, Alessandro [1 ]
Tarantino, Giovanni [1 ]
机构
[1] Univ Naples Federico II, Dept Clin & Expt Med, Reg Reference Ctr Coagulat Disorders, I-80131 Naples, Italy
关键词
Hepatic steatosis; Non-alcoholic fatty liver disease; Omega-3 polyunsaturated fatty acids; Animal models; ACTIVATED-RECEPTOR-ALPHA; ELEMENT-BINDING PROTEIN-1; AMELIORATE HEPATIC STEATOSIS; OXIDATIVE STRESS; INSULIN-RESISTANCE; GENE-EXPRESSION; ACID REGULATION; MURINE MODEL; MOLECULAR-MECHANISMS; METABOLIC SYNDROME;
D O I
10.3748/wjg.v18.i41.5839
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major health burden. It is the most important cause of chronic liver disease and a major independent cardiovascular risk factor. Lacking a definite treatment for NAFLD, a specific diet and an increase in physical activity represent the most commonly used therapeutic approaches. In this review, major literature data about the use of omega-3 polyunsaturated fatty acids (n-3 PUFAs) as a potential treatment of NAFLD have been described. n-3 PUFAs, besides having a beneficial impact on most of the cardio-metabolic risk factors (hypertension, hyperlipidemia, endothelial dysfunction and atherosclerosis) by regulating gene transcription factors [i.e., peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, sterol regulatory element-binding protein-1, carbohydrate responsive element-binding protein], impacts both lipid metabolism and on insulin sensitivity. In addition to an enhancement of hepatic beta oxidation and a decrease of the endogenous lipid production, n-3 PUFAs are able to determine a significant reduction of the expression of pro-inflammatory molecules (tumor necrosis factor-alpha and interleukin-6) and of oxygen reactive species. Further strengthening the results of the in vitro studies, both animal models and human intervention trials, showed a beneficial effect of n-3 PUFAs on the severity of NAFLD as expressed by laboratory parameters and imaging measurements. Despite available results provided encouraging data about the efficacy of n-3 PUFAs as a treatment of NAFLD in humans, well-designed randomized controlled trials of adequate size and duration, with histological endpoints, are needed to assess the long-term safety and efficacy of PUFA, as well as other therapies, for the treatment of NAFLD and non-alcoholic steatohepatitis patients. It is worthwhile to consider that n-3 PUFAs cannot be synthesized by the human body and must be derived from exogenous sources (fish oil, flaxseeds, olive oil) which are typical foods of the Mediterranean diet, known for its beneficial effects in preventing obesity, diabetes and, in turn, cardiovascular events. According to these data, it is important to consider that most of the beneficial effects of n-3 PUFAs can also be obtained by an equilibrate nutrition program. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:5839 / 5847
页数:9
相关论文
共 50 条
  • [21] Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
    He, Xi-Xi
    Wu, Xiao-Li
    Chen, Ren-Pin
    Chen, Chao
    Liu, Xiao-Gang
    Wu, Bin-Jiao
    Huang, Zhi-Ming
    [J]. PLOS ONE, 2016, 11 (10):
  • [22] The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs
    Yu, Le
    Yuan, Man
    Wang, Linchun
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2017, 33 (04) : 1022 - 1028
  • [23] Omega-3 fatty acids and liver disease
    Lee, Sang
    Gura, Kathleen M.
    Puder, Mark
    [J]. HEPATOLOGY, 2007, 45 (04) : 841 - 845
  • [24] Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease
    Alberti, Gigliola
    Gana, Juan Cristobal
    Santos, Jose L.
    [J]. NUTRIENTS, 2020, 12 (11) : 1 - 19
  • [25] Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease
    Lou, Da-jun
    Zhu, Qi-qian
    Si, Xu-wei
    Guan, Li-li
    You, Qiao-ying
    Yu, Zhong-ming
    Zhang, Ai-zhen
    Li, Duo
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (05) : 711 - 714
  • [26] Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
    Jump, Donald B.
    Lytle, Kelli A.
    Depner, Christopher M.
    Tripathy, Sasmita
    [J]. PHARMACOLOGY & THERAPEUTICS, 2018, 181 : 108 - 125
  • [27] Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents
    Athyros, Vasilios G.
    Mikhailidis, Dimitri P.
    [J]. CLINICAL LIPIDOLOGY, 2013, 8 (05) : 509 - 512
  • [28] Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids
    de Castro, Gabriela S.
    Calder, Philip C.
    [J]. CLINICAL NUTRITION, 2018, 37 (01) : 37 - 55
  • [29] Treatment of non-alcoholic fatty liver disease
    Takei, Yoshiyuki
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 79 - 80
  • [30] Treatment of Non-Alcoholic Fatty Liver Disease
    Scherer, Antonia
    Dufour, Jean-Francois
    [J]. DIGESTIVE DISEASES, 2016, 34 : 27 - 31